...First Patient Enrolled in Asia in Phase 3 NANORAY-312...
NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), and LianBio (Nasdaq: LIAN), today announced randomization of the first patient in Asia in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment...